Metabolic complications with the use of mTOR inhibitors for cancer therapy

BACKGROUND: mTOR inhibitors are now approved by regulatory agencies for the treatment of a variety of malignancies. The risk of metabolic complications with these agents is not well characterized. METHODS: PubMed was searched for articles published from 2001 until 2011. Eligible studies included pro...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Cancer Treat Rev
Main Authors: Sivendran, Shanthi, Agarwal, Neeraj, Gartrell, Benjamin, Ying, Jian, Boucher, Kenneth M., Choueiri, Toni K., Sonpavde, Guru, Oh, William K., Galsky, Matthew D.
Format: Artigo
Jezik:Inglês
Izdano: 2013
Teme:
Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC4744486/
https://ncbi.nlm.nih.gov/pubmed/23684373
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ctrv.2013.04.005
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki